OTCMKTS:UCBJY - UCB Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$47.48
▲ +0.04 (0.08%)
1 month | 3 months | 12 months
Get New UCB Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UCBJY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UCBJY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for UCB in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $47.48.
Hold
The current consensus among 4 contributing investment analysts is to hold stock in UCB. This rating has held steady since July 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
3/5/2021Morgan StanleyInitiated CoverageEqual Weight
i
3/3/2021UBS GroupReiterated RatingNeutral
i
1/22/2021BarclaysReiterated RatingOverweight
i
1/4/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
11/25/2020UBS GroupReiterated RatingNeutral
i
7/31/2020UBS GroupDowngradeBuy ➝ Neutral
i
7/28/2020JPMorgan Chase & Co.Reiterated RatingOverweight
i
1/5/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
i
10/29/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
i
9/5/2019BarclaysUpgradeUnderweight ➝ Equal Weight
i
5/30/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy
i
1/2/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
i
12/10/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
i
(Data available from 3/6/2016 forward)
UCB logo
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company offers Evenity for the treatment of osteoporosis; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 for immunology; and UCB0599 for neurology; and UCB0107 for progressive supranuclear palsy. Additionally, the company engages in contract manufacturing activities. It has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company was founded in 1928 and is headquartered in Brussels, Belgium.
Read More

Today's Range

Now: $47.48
$45.85
$47.54

50 Day Range

MA: $52.17
$47.44
$53.93

52 Week Range

Now: $47.48
$32.45
$68.00

Volume

13,290 shs

Average Volume

18,244 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of UCB?

The following Wall Street research analysts have issued research reports on UCB in the last twelve months: Barclays PLC, JPMorgan Chase & Co., Morgan Stanley, and UBS Group AG.
View the latest analyst ratings for UCBJY.

What is the current price target for UCB?

0 Wall Street analysts have set twelve-month price targets for UCB in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for UCB in the next year.
View the latest price targets for UCBJY.

What is the current consensus analyst rating for UCB?

UCB currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in UCBJY, but not buy more shares or sell existing shares.
View the latest ratings for UCBJY.

What other companies compete with UCB?

How do I contact UCB's investor relations team?

The company's listed phone number is 32 2 559 99 99. The official website for UCB is www.ucb.com.